Finding Immune Nascent Type 1 Diabetes

Finding Immune Nascent Type 1 Diabetes (FIND T1D)

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07663136

Acronym

FIND T1D

Enrollment

3800

Registered

2026-06-23

Start date

2026-06-01

Completion date

2029-06-01

Last updated

2026-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adult, Type 1 Diabetes (T1D)

Keywords

type 1 diabetes home screening kit, type 1 diabetes

Brief summary

The goal of this clinical trial is to understand how many individuals who previously participated in the Indiana Biobank will return a type 1 diabetes home screening kit based upon different methods of recruitment communication. The main question it aims to answer is: What form of recruitment communication is most effective for completing a type 1diabetes home screening kit? Researchers will compare two types of recruitment contact: email and mail based communication (low-touch) versus phone contact and follow-up by a research team member (high-touch). Participants will be contacted either via email/mail or by phone and asked if they want to complete a type 1 diabetes home screening kit.

Interventions

BEHAVIORALphone call

Recruitment through phone call

BEHAVIORALemail/mail

Recruitment through email and mail

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

1 Years to 99 Years

Healthy volunteers

Yes

Inclusion criteria

* Participant must be in Indiana Biobank * Participant must be able to provide consent * Ages 1-99 including pregnant women

Exclusion criteria

* Refusal to sign informed consent for home screening is exclusionary for the home screening portion of the study * While other medical conditions are allowable prior diabetes diagnosis is exclusionary for home autoantibody screening

Design outcomes

Primary

Measure	Time frame	Description
Rates of Returned Home Screening Kits	From enrollment to the end of study at 3 years.	The number of returned screening kits versus the number that were not returned by consented participants.
Rates of Consent	From enrollment to the end of study at 3 years.	The number of participants who consent versus the number of participants who do not consent.

Secondary

Measure	Time frame
Percent of Kits with Adequate Blood Volume	From enrollment to the end of study at 3 years.

Countries

United States

Contacts

CONTACTMaureen Mullen Montagano

findt1d@iu.edu317-274-7677

CONTACTAdarsh Viswanath

findt1d@iu.edu317-278-5033

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 24, 2026